Packaged Device Or Kit Patents (Class 435/810)
-
Patent number: 11833258Abstract: The present disclosure relates to a method of steam-sterilizing liquid-filled medical devices, e.g., filtration and/or diffusion devices like ultrafilters and capillary dialyzers.Type: GrantFiled: August 16, 2018Date of Patent: December 5, 2023Assignee: GAMBRO LUNDIA ABInventors: Ralf Flieg, Wolfgang Freudemann, Torsten Knoer
-
Patent number: 9902775Abstract: Antibodies and antibody fragments that bind to BDCA2 are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a plasmacytoid dendritic cell, inhibit production or secretion of inflammatory cytokines and chemokines, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.Type: GrantFiled: December 10, 2013Date of Patent: February 27, 2018Assignee: Biogen MA Inc.Inventors: Justin A. Caravella, Ellen A. Garber Stark, Dania Mounir Rabah, Frederick R. Taylor
-
Patent number: 9034657Abstract: A two step lateral flow assay method for identifying IgE antibodies in a sample comprises applying a sample to a sample port of a device, wherein the device is adapted to deliver the sample to a lateral flow matrix having a plurality of IgE antigen species immobilized at respective positions at a first location; allowing the sample to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species to a second location downstream of the first location; and, after a predetermined period of time, applying liquid buffer to the lateral flow matrix to mobilize labeled reagent which is adapted to bind anti-IgE antibody and which is dried on the lateral flow matrix at a location upstream of the sample port delivery of the sample to the lateral flow matrix, and allowing labeled reagent mobilized by the liquid buffer to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species and bind with any IgE antibody bound to the immobilized IgE antigen species, aType: GrantFiled: December 8, 2010Date of Patent: May 19, 2015Assignee: Phadia ABInventors: Gerd Rundström, Per Matsson, Paul Christopher
-
Patent number: 9029508Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: GrantFiled: April 28, 2009Date of Patent: May 12, 2015Assignee: AbbVie Inc.Inventors: Tariq Ghayur, Susan E. Morgan-Lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying
-
Patent number: 9005991Abstract: Devices and methods for testing a biological sample for an analyte of interest are provided that make use of a reaction chamber for receiving a reaction mixture, a housing positioned below the reaction chamber for receiving a test cassette, and a door that is positioned in the top portion of the housing. The door includes a ramp that extends downwardly into the housing such that biasing the ramp upwards opens the door into the cavity of the reaction chamber and places the reaction chamber in fluid communication with the insertion area to thereby allow the reaction mixture to flow onto a test cassette and allow for the determination of an amount of an analyte of interest.Type: GrantFiled: January 5, 2012Date of Patent: April 14, 2015Assignee: American Bio Medica CorporationInventors: Douglas Casterlin, Larry Ferringo
-
Patent number: 8992865Abstract: The present invention relates to a sealing device for closing an introduction aperture, the sealing device comprising a fixed support and a shutter mounted movably in translation relative to the support between an extended position and a final retracted position, wherein the sealing device is in a final retracted configuration and wherein the shutter closes introduction aperture. The device includes locking means for preventing any movement of the shutter when it is in the final retracted position. The sealing device further comprises an intermediate retracted configuration, wherein the shutter is at least partly retracted. The sealing device also comprises motion guiding means for guiding the movement of the shutter and designed so that the extension of the shutter is required to move the shutter from the intermediate retracted position to the final retracted position.Type: GrantFiled: September 27, 2012Date of Patent: March 31, 2015Assignee: Biocartis NVInventors: Rob Bosma, Ronald De Gier
-
Patent number: 8980274Abstract: The invention provides Ehrlichia canis antigens that can be used to detect E. canis infected animals regardless of whether the animals have been vaccinated for E. canis. The invention also provides compositions and methods for determining the presence of E. canis antigens and antibodies.Type: GrantFiled: January 21, 2011Date of Patent: March 17, 2015Assignee: IDEXX Laboratories, Inc.Inventors: Eugene Regis Krah, III, Melissa Beall, Thomas Patrick O'Connor, Jr., Ramaswamy Chandrashekar
-
Patent number: 8975014Abstract: The invention herein disclosed provides for compositions, methods for synthesizing said compositions, and methods for using said compositions, wherein the compositions and methods may be used to bind to and/or deactivate a poison oak oil, such as urushiol. The compositions and methods can be used to treat and/or reduce an inflammatory reaction and/or hypersensitivity to natural compounds found in poison oak, poison ivy, poison sumac, mango, lac tree, and cashew nut.Type: GrantFiled: May 6, 2014Date of Patent: March 10, 2015Assignee: The Regents of the University of CaliforniaInventor: Rebecca Braslau
-
Patent number: 8975032Abstract: The object of the present invention is to provide: a test kit for an antibody titer or an antibody against a periodontal disease-causing bacterium in a blood sample, which enables the testing on a periodontal disease in patients having a wide scope of immunotypes with high accuracy and can be treated by an automated device at a high speed; a periodontal disease-causing bacterium antigen protein which can be suitably used in the kit; a method for testing an antibody titer or the presence of an antibody in a blood sample using the kit; and a kit for typing strains of Porphyromonas gingivalis.Type: GrantFiled: October 18, 2011Date of Patent: March 10, 2015Assignee: Sunstar Inc.Inventor: Mikio Nozoe
-
Patent number: 8969527Abstract: Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.Type: GrantFiled: May 30, 2012Date of Patent: March 3, 2015Assignees: The Regents of the University of Michigan, The Brigham and Women's Hospital, Inc.Inventors: Scott Tomlins, Daniel Rhodes, Arul Chinnaiyan, Rohit Mehra, Mark A. Rubin, Xiao-Wei Sun, Sven Perner, Charles Lee, Francesca Demichelis
-
Patent number: 8969526Abstract: The invention relates to engineered polypeptides comprising Fc variants and their uses. More specifically, Fc variants are described exhibiting reduced effector function. These variants cause a benefit for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector function elicited by antibodies.Type: GrantFiled: March 27, 2012Date of Patent: March 3, 2015Assignee: Roche Glycart AGInventors: Monika Baehner, Stefan Jenewein, Manfred Kubbies, Ekkehard Moessner, Tilman Schlothauer
-
Patent number: 8961976Abstract: The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.Type: GrantFiled: December 19, 2013Date of Patent: February 24, 2015Assignee: Biogen Idec Ma Inc.Inventors: Herman Van Vlijmen, Alexey Lugovskoy, Karl Hanf
-
Patent number: 8945637Abstract: The present invention includes compositions and methods for cleaning, treating, protection and resolution of decubitus ulcers comprising: a first composition comprising a wound cleaning solution comprising aloe vera gel comprising at least 5,000 MPS, a balanced salt solution; and a second composition comprising a wound healing gel comprising aloe vera gel comprising at least 10,000 MPS, a thickening agent, and one or more preservatives and, optionally, a third composition comprising a moisture barrier cream comprising a vegetable-based emulsifier, a cosmetic ester for dry skin that has low occlusivity, an ester-based emollient that is oxidation stable and has low occlusivity; a beeswax; a hydrogenated oil, glycerin, a buffering agent, aloe vera gel comprising at least 2,000 MPS and water.Type: GrantFiled: September 27, 2013Date of Patent: February 3, 2015Assignee: Aloe Bioscience, LLCInventor: Ivan E. Danhof
-
Patent number: 8945926Abstract: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided.Type: GrantFiled: December 16, 2011Date of Patent: February 3, 2015Assignee: The Scripps Research InstituteInventors: Jason W. Chin, T. Ashton Cropp, J. Christopher Anderson, Peter G. Schultz
-
Patent number: 8940527Abstract: The present invention provides an apparatus for fluid sample collection and analyte testing, including a sample receiving member and at least one membrane test strip, and optionally a sample retention member, fingerprint acquisition pad, and/or fluid collector. It also provides a fluid collection apparatus having an absorbent material, compression element, and closure element, and optionally a lid that allows the apparatus to be used in conjunction with a fluid container. Also provided are methods of collecting, testing, and retaining a fluid sample and verifying the identity of one or more individuals associated with the sample, such as the test subject, test administrator, and/or witnesses.Type: GrantFiled: December 22, 2010Date of Patent: January 27, 2015Assignee: Lamina Equities Corp.Inventor: Raouf A. Guirguis
-
Patent number: 8936933Abstract: A method of processing a sample may include introducing a sample into a vessel, the vessel having proximal and distal ends, the sample being introduced into the proximal end of the vessel; incubating the sample in the vessel with a substance capable of specific binding to a preselected component of the sample; propelling components of the incubated sample, other than the preselected component, toward the proximal end of the vessel by clamping the vessel distal to the incubated sample and compressing the vessel where the incubated sample is contained; propelling the preselected component toward a distal segment of the vessel by clamping the vessel proximal to the preselected component and compressing the vessel where the preselected component is contained; and mixing the preselected component with a reagent in the distal segment of the vessel.Type: GrantFiled: May 18, 2010Date of Patent: January 20, 2015Assignee: IQumm, Inc.Inventors: Shuqi Chen, Lingjun Chen
-
Patent number: 8906633Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.Type: GrantFiled: December 20, 2011Date of Patent: December 9, 2014Assignee: Randox Laboratories LimitedInventors: Elouard Benchikh, Stephen Peter Fitzgerald, Paul John Innocenzi, Philip Andrew Lowry, Ivan Robert McConnell
-
Patent number: 8906635Abstract: Methods of diagnosing Clostridium difficile infection and compounds used in the methods are provided. The diagnostic methods are specific and sensitive methods for detecting a host cell response and, in some aspects, a target response, i.e. a Clostridium difficile toxin, in an individual infected with Clostridium difficile. The methods comprise detecting in a stool specimen or fluid exposed to the stool specimen a Clostridium difficile toxin, or a fragment thereof, and an increase in a colonic epithelial cell protein exemplified by a non-muscle tropomyosin. Also provided are kits comprising reagents for detecting host cell proteins and Clostridium difficile toxins.Type: GrantFiled: February 23, 2012Date of Patent: December 9, 2014Assignee: Northshore University HealthsystemInventors: Jian-Ping Jin, Lance R. Peterson
-
Patent number: 8900881Abstract: The present invention relates to a quantitative assay device and a method for the determination of an analyte, based on a test strip, which contains a porous test membrane allowing for capillary flow of the analyte and complexes of the analyte, a porous upstream membrane in fluid connection with the test membrane and a porous downstream membrane in fluid connection with the test membrane, wherein the test membrane contains two bands having deposited on there high and low concentrations of different calibrator agents and a test band capable of reacting with conjugated analyte complexes giving rise to a measurable signal.Type: GrantFiled: September 12, 2011Date of Patent: December 2, 2014Inventor: Jin Po Lee
-
Patent number: 8877515Abstract: It is an object of the present invention to provide a measurement kit for developing a first developing solution and a second developing solution from different directions to suppress background noise, and an immunochromatography kit. The present invention provides a measurement kit, which comprises a first developing member for supplying a first developing solution and a second developing member for supplying a second developing solution, wherein the developing direction of the first developing solution is allowed to intersect with the developing direction of the second developing solution, so that development is carried out by developing the first and second developing solutions in different developing directions, and a water absorbent portion is established on the downstream of each of the developing directions.Type: GrantFiled: July 7, 2011Date of Patent: November 4, 2014Assignee: FUJIFILM CorporationInventors: Hiroyuki Chiku, Junichi Katada, Hideyuki Karaki, Hiroki Terada
-
Patent number: 8865458Abstract: The present invention includes but is not limited to a specimen collection device that includes a chamber capable of collecting a specimen, a specimen passage slot, a reservoir, a reservoir seal, and a test device. A sample or specimen added to the chamber flows through the specimen passage slot into the reservoir. Flow into the reservoir may be limited by the reservoir seal. The test device positioned within the reservoir detects the presence or concentration of an analyte within the sample or specimen.Type: GrantFiled: February 25, 2013Date of Patent: October 21, 2014Assignee: Alere Switzerland GmbHInventors: James T. Ramsey, Larry Hartselle
-
Patent number: 8859200Abstract: The present invention provides a reagent for analysis of immature leukocytes comprising: a surfactant which can damage cell membranes of erythrocytes and mature leukocytes, a solubilizing agent which can shrink the damaged blood cells and at least one dye for staining nucleic acid selected from the dyes of the formulae (I) and (II), wherein X? is an anion.Type: GrantFiled: June 25, 2008Date of Patent: October 14, 2014Assignee: Sysmex CorporationInventors: Yukiko Kataoka, Tomohiro Tsuji, Shinichiro Oguni, Ayumu Yoshida, Masaki Abe
-
Patent number: 8846047Abstract: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.Type: GrantFiled: October 4, 2010Date of Patent: September 30, 2014Assignee: The Feinstein Institute for Medical ResearchInventors: Walter Newman, Shixin Qin, Theresa L. O'Keefe, Robert A. Obar
-
Patent number: 8835182Abstract: The present invention provides an immunochromatographic device, which contains the following (a) and (b): (a) a first device part holding a first insoluble carrier used for developing a complex formed with an analyte and a labeling substance comprising a metal labeled with a first binding substance that can bind to the analyte and capturing the analyte and the labeling substance at a reaction portion containing a second binding substance that can bind to the analyte, and (b) a second device part holding a second insoluble carrier used for developing a liquid and a third insoluble carrier used for absorbing a liquid, in such a way that the first insoluble carrier does not come into contact with the second insoluble carrier and the third insoluble carrier.Type: GrantFiled: January 24, 2013Date of Patent: September 16, 2014Assignee: FUJIFILM CorporationInventors: Junichi Katada, Hideyuki Karaki, Takayoshi Oyamada
-
Patent number: 8828947Abstract: The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same.Type: GrantFiled: February 21, 2012Date of Patent: September 9, 2014Assignee: Immunex CorporationInventors: Wayne Richard Gombotz, Richard Louis Remmele, Jr.
-
Patent number: 8815609Abstract: A lateral flow device includes a sample compressor and a test strip comprising a diverting zone. The diverting zone, which may include a barrier and/or a gap or ditch, stops or impedes flow. Flow is reinitiated and diverted into an alternate plane by compression of a sample compressor. Flow returns to the original, lateral plane, at the end of the diverting zone.Type: GrantFiled: March 7, 2013Date of Patent: August 26, 2014Assignee: Rapid Pathogen Screening, Inc.Inventors: Uma Mahesh Babu, Robert P. Sambursky, Peter Condon, Robert W. VanDine
-
Patent number: 8815573Abstract: The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells. The invention also provides kits for use in the cultivation of a mammalian epithelial cell that comprise one or more containers, wherein a first container contains the culture medium of the invention. These kits may further comprise one or more additional containers containing one or more supplements.Type: GrantFiled: March 20, 2013Date of Patent: August 26, 2014Assignee: Life Technologies CorporationInventors: Stephen F. Gorfien, Richard Fike, Glenn P. Godwin, Joyce L. Wolanske, David A. Epstein, Dale Gruber, Don McClure, Paul J. Price
-
Patent number: 8802427Abstract: The present invention is related to a diagnostic test kit that assesses ovarian reserve by measuring Follicle Stimulating Hormone (FSH) in a liquid sample. The sample can be deposited on a first portion of the device for transport to a second portion of the device. The device can include a release medium formed of a first material and including a detectable label thereon and a capture medium, including a test site, in fluid communication with the release medium and formed of a second, different material.Type: GrantFiled: June 9, 2009Date of Patent: August 12, 2014Assignee: Church & Dwight Co., Inc.Inventors: Albert R. Nazareth, Timothy Snowden, Mary Beth Boyle, Shang Li
-
Patent number: 8795661Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: GrantFiled: May 20, 2013Date of Patent: August 5, 2014Assignees: MedImmune, LLC, Board of Regents, The University of Texas SystemInventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward Ober
-
Patent number: 8778657Abstract: The present invention discloses culture medium unit doses for cultivating microorganisms comprising at least two compositions, each composition packaged in a composition unit dose of a predetermined amount, the composition unit doses being used for combining one of each composition unit dose forming the culture medium unit dose. The composition unit doses being packaged separately and individually until a time the culture medium unit dose is to be prepared for use for cultivation of microorganisms, wherein the time one of each composition unit dose are combined thereby forming the culture medium unit dose. The invention also discloses a method of manufacturing the composition unit doses, and a kit for cultivating microorganisms, the kit comprising a combination of the composition unit doses.Type: GrantFiled: October 17, 2012Date of Patent: July 15, 2014Assignee: Hardy DiagnosticsInventors: Gary A. Peterson, Andre Y. Hsiung
-
Patent number: 8771710Abstract: The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the Leishmania antigens K26, K39, and K9. The fusion protein is particularly useful in the diagnosis of leishmaniasis, particularly visceral leishmaniasis in animals such as humans and dogs.Type: GrantFiled: July 27, 2012Date of Patent: July 8, 2014Assignee: Infectious Disease Research InstituteInventors: Ajay Bhatia, Steven G. Reed
-
Patent number: 8715649Abstract: Embodiments herein illustrate methods and compositions for treating medical disorders. In certain embodiments, compositions and methods relate to reducing, inhibiting or treating graft rejection, transplant rejection or diabetes in a subject. Other embodiments herein relate to compounds including naturally occurring and synthetic mutant compositions of alpha-1 antitrypsin, wherein the alpha-1 antitrypsin has no significant serine protease inhibitor activity.Type: GrantFiled: January 30, 2009Date of Patent: May 6, 2014Inventors: Charles A. Dinarello, Eli C. Lewis
-
Patent number: 8703504Abstract: A lateral flow, membrane-based assay device for detecting the presence or quantity of an analyte residing in a test sample is provided. The device utilizes phosphorescence to detect the signals generated by excited phosphorescent labels. The labels may have a long emission lifetime so that background interference from many sources, such as scattered light and autofluorescence, is practically eliminated during detection. In addition, the phosphorescent labels may be encapsulated within particles to shield the labels from quenchers, such as oxygen or water, which might disrupt the phosphorescent signal.Type: GrantFiled: September 4, 2013Date of Patent: April 22, 2014Assignee: Kimberly-Clark Worldwide, Inc.Inventor: Xuedong Song
-
Patent number: 8697352Abstract: The present invention is related to nucleic acid sequences that can be used in the field of virus diagnostics, more specifically the diagnosis of infections with the AIDS causing Human Immuno-deficiency Virus (HIV). With the present invention nucleotide sequences are provided that can be used as primers and probes in the amplification and detection of HIV-1 nucleic acid. The oligonucleotide sequences provided with the present invention are located in the LTR part of the HIV viral genome. It has been found that, by using the sequences of the present invention in methods for the amplification and detection of nucleic acid a sensitive and specific detection of HIV-1 can be obtained. The benefit of the sequences of the present invention primarily resides in the fact that, with the aid of primers and probes comprising the sequences according to the invention the nucleic acid of all presently known subtypes of HIV-1 can be detected with high accuracy and sensitivity.Type: GrantFiled: April 18, 2005Date of Patent: April 15, 2014Assignee: bioMerieux, B.V.Inventors: Jaap Goudsmit, Pieter Oudshoorn, Suzanne Jurriaans, Vladimir Vladimirovich Lukashov
-
Patent number: 8691956Abstract: This invention relates to a monoclonal antibody against a human HIG-1 polypeptide, the antibody binding to at least one epitope included in the amino acid sequence at positions 1-19 of a human HIG-1 polypeptide; an antibody fragment derived from the antibody; a DNA comprising a base sequence encoding a variable region of the antibody; an expression vector comprising the DNA; a cell line producing the antibody; a reagent for detecting a human HIG-1 polypeptide comprising the antibody or the antibody fragment, and a method for detecting a human HIG-1 polypeptide using the antibody or the antibody fragment.Type: GrantFiled: September 29, 2010Date of Patent: April 8, 2014Assignee: Ishihara Sangyo Kaisha, Ltd.Inventors: Fuminori Kato, Yoshitaka Kondo
-
Patent number: 8691568Abstract: The invention provides a method for preparing cell populations with anti-tumor immune response activity, which includes co-culturing tumor and mononuclear cell in a three-dimensional cell culture device, separating and amplifying the cell populations with anti-tumor immune response activity from the cultures. The present invention, at the same time, discloses the cell populations with anti-tumor immune response activity obtained by the method and the kit comprising the cell populations.Type: GrantFiled: November 22, 2006Date of Patent: April 8, 2014Inventors: Hua Liu, Wei Yang
-
Patent number: 8680246Abstract: The present disclosure provides lysyl oxidase-like-2 (LOXL2) polypeptide binding agents, including, for example, antibodies that specifically bind a LOXL2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided.Type: GrantFiled: February 4, 2011Date of Patent: March 25, 2014Assignee: Gilead Biologics, Inc.Inventors: Scott Alan McCauley, Hector Rodriguez, Carlos Aurelio Garcia, Victoria Smith
-
Patent number: 8679790Abstract: The invention provides compositions and methods for enhanced gene expression. The invention provides a composition comprising a 28-codon leader sequence operably linked to a desired gene which encodes the desired protein.Type: GrantFiled: January 4, 2011Date of Patent: March 25, 2014Assignee: The Trustees of the University of PennsylvaniaInventors: Joshua B. Plotkin, Grzegorz Kudla
-
Patent number: 8679770Abstract: The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular N. meningitidis. The SBA assay is the most important method for measuring functional activity of serum antibodies against meningococcus. In order to determine whether a subject or a population is seropositive against invasive meningococcus the SBA test should ideally be both sensitive and specific. The inventors have found the standard N. meningitidis serotype A and W SBAs can be significantly improved in this regard.Type: GrantFiled: September 5, 2005Date of Patent: March 25, 2014Assignee: Glaxo Smith Kline Biologicals S.A.Inventors: Isabel De Vleeschauwer, Nathalie Durant, Jan Poolman, Vincent Weynants
-
Patent number: 8663655Abstract: The present invention relates to peptides, nucleic acids and methods for transforming a bacterium belonging to the Streptococcus genus by natural competence and their use in the food and feed industry.Type: GrantFiled: June 23, 2010Date of Patent: March 4, 2014Assignee: Dupont Nutrition Biosciences APSInventors: Patrick Boyaval, Christophe Fremaux, Pascal Hols, Laetitia Fontaine, Philippe Horvath
-
Patent number: 8647625Abstract: The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.Type: GrantFiled: July 26, 2005Date of Patent: February 11, 2014Assignee: Biogen Idec MA Inc.Inventors: Herman Van Vlijmen, Alexey Alexandrovic Lugovskoy, Karl J. M. Hanf
-
Patent number: 8647629Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: May 14, 2009Date of Patent: February 11, 2014Assignee: Immatics Biotechnologies GmbHInventors: Hans-Georg Rammensee, Stefan Stevanovic, Cécile Gouttefanges, Toni Weinschenk, Peter Lewandrowski
-
Patent number: 8637319Abstract: A method for detecting human or animal blood traces on a surface is described. The method is fundamentally based on the reaction of luminol and includes the preliminary operation of atomizing an inorganic powder suspension, such as titania, silica, alumina, hydroxyapatite, or the like, onto the surface to be investigated, after which a composition of luminol, a peroxidic oxidizing agent and an alkaline agent in an amount providing a pH within the range of 10 to 14, is atomized on the surface. A kit for carrying out the detection method of the invention is also described.Type: GrantFiled: December 2, 2009Date of Patent: January 28, 2014Assignee: Universita' Degli Studi di TorinoInventors: Gianmario Martra, Simone Priante, Marco Vincenti
-
Patent number: 8637259Abstract: The invention relates to the identification of carboxylic acids, present in human sweat, as natural ligands of a specific subgroup of seven olfactory receptor (OR) belonging to class 1 within the OR classification. The invention encompasses the use of the interaction of OR polypeptides and carboxylic acids as the basis of screening assays for agents that specifically modulate the activity of the seven ORs of the invention.Type: GrantFiled: February 9, 2011Date of Patent: January 28, 2014Assignee: ChemCom S.A.Inventors: Pierre Chatelain, Alex Veithen
-
Patent number: 8617871Abstract: The present invention relates to an improved culture medium and method for the enhanced growth and detection of Mycobacterium growth. The invention further relates to an improved mycobacterial reagent system or kit that can be used for the enhanced growth and detection of Mycobacterium.Type: GrantFiled: December 21, 2012Date of Patent: December 31, 2013Assignee: bioMerieux, Inc.Inventors: Parampal Deol, Leticia Barton, Yoany Portilla, Douglas Lovern
-
Patent number: 8614101Abstract: Devices and methods incorporate lysis agents into a point-of-care testing device. The sample is loaded, and then the sample travels until it encounters a lysis agent. The lysis agent is preferably pre-loaded onto the collection device. In a preferred embodiment, the initially lysis agent is localized between the sample application zone and the conjugate zone. The lysis agent is preferably soluble or miscible in the sample transport liquid, and the lysis agent is solubilized and activated upon contact with the sample transport liquid. The sample transport liquid then contains both lysis agent in solution or suspension and sample components in suspension. Any lysis-susceptible components in a sample, then being exposed in suspension to the lysis agent, are themselves lysed in situ. The running buffer then carries the analyte, including any lysis-freed components, to the detection zone.Type: GrantFiled: July 14, 2009Date of Patent: December 24, 2013Assignee: Rapid Pathogen Screening, Inc.Inventors: Robert W. VanDine, Uma Mahesh Babu, Robert P. Sambursky
-
Patent number: 8609817Abstract: Monoclonal antibodies are provided that bind to the N-terminus of human hepcidin-25 and are characterized as having high affinity and selectivity for the polypeptide. The antibodies of the invention are useful for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment of various disorders, such as anemia, in a human subject. The antibodies of the invention are also useful as analytical tools, such as in sandwich ELISA.Type: GrantFiled: July 29, 2009Date of Patent: December 17, 2013Assignee: Eli Lilly and CompanyInventors: Donmienne Doen Mun Leung, Peng Luan, Ying Tang, Derrick Ryan Witcher, Pia Pauliina Yachi
-
Patent number: 8603835Abstract: Test cells have a first sorbent strip with a sample receiving location and defining a first migration path, a distinct second sorbent strip which receives buffer solution and at least partially defines a second migration path distinct from and elongated relative to the first migration path, conjugate supported by the second strip, a test site located at a junction of the first and second strips and having an immobilized ligand-binding mechanism, and a divider which directs a first amount of the buffer to the first strip to move the sample to the test site and a second amount to the second strip to move the conjugate to the test site. The first and second migration paths have first and second lengths chosen so that ligand in the sample reaches the test site and binds to the immobilized ligand-binding mechanism prior to the conjugate reaching the test site.Type: GrantFiled: February 10, 2011Date of Patent: December 10, 2013Assignee: Chembio Diagnostic Systems, Inc.Inventor: Javanbakhsh Esfandiari
-
Patent number: 8597897Abstract: The present invention relates to a method of rapidly detecting microorganisms using nanoparticles, and more particularly to a method and device of rapidly detecting microorganisms by adding, to the microorganisms to be detected, nanoparticles having immobilized thereon an antibody that binds specifically to the microorganisms to be detected, subjecting the mixture to an immune reaction to form a reaction solution, passing the reaction solution through a microorganism-concentrating film to concentrate the microorganisms, capturing microorganisms, which was immune-reacted with the antibody-immobilized nanoparticles, by a microorganism-capturing filtration membrane, and determining the presence and concentration of the microorganisms.Type: GrantFiled: November 24, 2010Date of Patent: December 3, 2013Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Min Gon Kim, Yong Beom Shin, Yoon Joo Sung
-
Patent number: 8580509Abstract: Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.Type: GrantFiled: May 30, 2012Date of Patent: November 12, 2013Assignees: The Regents of The University of Michigan, The Brigham and Women's Hospital, Inc.Inventors: Scott Tomlins, Daniel Rhodes, Arul Chinnaiyan, Rohit Mehra, Mark A. Rubin, Xiao-Wei Sun, Sven Perner, Charles Lee, Francesca Demichelis